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Abstract
The phenotypic heterogeneity that characterizes human cancers reflects the enormous genetic complexity of the oncogenic
process. This complexity can also be seen in mouse models where it is frequently observed that in addition to the initiating
genetic alteration, the resulting tumor harbors additional, somatically acquired mutations that affect the tumor phenotype.
To investigate the role of genetic interactions in the development of tumors, we have made use of the Em-myc model of pre-
B and B cell lymphoma. Since various studies point to a functional interaction between Myc and the Rb/E2F pathway, we
have investigated the role of E2F activities in the process of Myc-induced lymphomagenesis. Whereas the absence of E2F1
and E2F3 function has no impact on Myc-mediated tumor development, the absence of E2F2 substantially accelerates the
time of tumor onset. Conversely, tumor development is delayed by the absence of E2F4. The enhanced early onset of
tumors seen in the absence of E2F2 coincides with an expansion of immature B lineage cells that are likely to be the target
for Myc oncogenesis. In contrast, the absence of E2F4 mutes the response of the lineage to Myc and there is no expansion
of immature B lineage cells. We also find that distinct types of tumors emerge from the Em-myc mice, distinguished by
different patterns of gene expression, and that the relative proportions of these tumor types are affected by the absence of
either E2F2 or E2F4. From these results, we conclude that there are several populations of tumors that arise from the Em-myc
model, reflecting distinct populations of cells that are susceptible to Myc-mediated oncogenesis and that the proportion of
these cell populations is affected by the presence or absence of E2F activities.
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Introduction
A hallmark of human cancer is genetic complexity, reflecting
the acquisition of multiple mutations and gene rearrangements
that give rise to the tumor phenotype. Indeed, recent large-scale
DNA sequencing efforts have provided direct evidence for this
complexity, revealing large numbers of alterations that character-
ize various tumor types [1–4]. Undoubtedly, this genetic
complexity of cancer underlies much of the challenge in
developing effective therapeutic strategies. Not only is it likely
that combinations of drugs will be necessary to match the
complexity and effectively treat these tumors but equally
important is the ability to identify subgroups of cancers that
represent more homogeneous mechanisms of disease.
An ability to model the complexity that gives rise to the tumor
heterogeneity seen in human cancers would clearly enhance the
understanding of the oncogenic process but also would enable the
development and testing of combination therapeutics that might
match this complexity. Mouse models of cancer have generally
employed the use of an activated oncogene or the disruption of a
tumor suppressor gene to initiate the oncogenic process. Although
this represents a defined genetic alteration, it is also true that in
most instances this single event is not sufficient to allow for tumor
development. This can be seen in the often protracted latency of
tumor development as well as the identification of specific
additional genetic alterations that appear in these tumors.
An example of a well-studied genetic model for the analysis of
pre-B and B cell lymphoma is the Em-myc transgenic mouse. In the
Em-myc transgenic mouse c-myc is constitutively expressed in the B
lineage [5,6]. The resulting polyclonal expansion of pre-B cells is
initially limited by increased apoptosis [7]. Additional mutations,
many of which inactivate the p53 tumor suppressor pathway [8],
then arise. This leads to the emergence of a clonal pre-B or B cell
lymphoma by six months of age in mice of a mixed C57Bl/6 and
129 strain background.
Myc has been shown to induce a large number of genes that
contribute to cell proliferation. These include the direct transcrip-
tional activation of D cyclin genes, the cdk4 gene encoding the
kinase partner for cyclin D, and the Cdc25A gene encoding the
phosphatase that removes negative regulatory phosphates from the
Cdks. The induction of Cyclin D/cdk4 activity leads directly to the
phosphorylation of Rb and thus activation of E2Fs. Numerous
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in the regulation of cellular proliferation. The majority of genes
encoding DNA replication and mitotic activities are under the
control of E2F proteins. Indeed, recent experiments provide
evidence for a role for E2Fs in coordinating transcriptional
regulatory events at G1/S and G2/M [9–11]. Other work has
shown that E2Fs also link this critical proliferative pathway with
the p53 response through a capacity to induce the p19ARF/
Mdm2 pathway leading to the accumulation of p53 protein
[12,13]. As such, E2Fs provide a mechanism to directly link the
control of cell proliferation with the determination of cell fate. In
addition to the connection between Myc and E2F in the control of
cellular proliferation, Myc expression couples cellular proliferation
with the induction of apoptosis under specific growth conditions
where survival growth factors are limiting. Myc-induced apoptosis
is largely dependent upon p53 signaling and, similar to E2F1,
involves the induction of p19
ARF, inhibition of Mdm2, and
elevated p53 [14].
The shared functional properties of the Myc and E2F
transcription factors, coupled with the finding that Myc can
induce E2F gene expression [15,16], raise the possibility that Myc
function might be mediated, at least in part, through the action of
the E2F transcription factors. Indeed, work by the Bernards
laboratory revealed that in addition to targeting p27
Kip1, the
mitogenic activity of Myc likely involves regulation of E2Fs [17].
This possibility has been more directly assessed using mouse
embryo fibroblasts (MEFs) from embryos deleted for specific E2F
genes to evaluate the functional relationship between Myc and
various E2F proteins [18]. Experiments using these E2F-deficient
MEFs showed that the ability of Myc to induce S phase in the
absence of other mitogens is severely impaired in MEFs deleted for
E2f2 or E2f3, but not E2f1 or E2f4. In contrast, Myc induced
apoptosis in primary serum-deprived MEFs was delayed in cells
deleted for E2f1, but not affected by E2f2 or E2f3 deletion. Thus,
at least in cell culture, the induction of specific E2F activities is an
essential downstream event in the Myc pathway that controls cell
proliferation versus apoptosis, and some of the functions of Myc,
such as the induction of p19
ARF and p53 could be explained, at
least in part, with one pathway leading through E2F activation.
To address the significance of the Myc-E2F connection in a
relevant, in vivo setting, we have made use of a series of E2F-
deficient mouse strains, in combination with the Em-myc transgenic
model of lymphomagenesis (MGI:2448238), to investigate whether
deficiencies in E2F1, E2F2, E2F3 or E2F4 (MGI:1857424,
2179111, 2177428 and 1888951) can influence Myc’s oncogenic
potential. We find that there is a critical role for two E2F activities
in affecting the potential for Myc-induced oncogenesis.
Results
As a prelude to the investigation of a role for E2F activity in
Myc-mediated oncogenesis, we analyzed the pattern of tissue-
specific expression of the various E2F genes. RNA was prepared
from selected tissues of wild type mice and then analyzed by
quantitative RT-PCR. E2f1 and E2f3 genes were widely expressed
whereas expression of the E2f2 gene was largely restricted to the
hematopoietic tissues assayed including bone marrow, spleen, and
thymus (Figure S1A). Please note that Text S1 (Supporting
Materials and Methods) describes the procedures specific to
Figures S1, S2, S3, S4, S5, S6, S7, S8, S9, and S10. This restricted
E2f2 expression pattern at the RNA level was recapitulated at the
protein level (Figure S1B). E2f4, while expressed widely at the
RNA level, was also particularly strongly expressed in hemato-
poietic tissues at the protein level (Figure S1C) [19]. While we did
not measure E2F5 in these assays, it has previously been shown
that the expression of this E2F family member is restricted to the
differentiating epithelial layers of the skin, intestine and brain
[20,21]. As such, we chose to focus our studies on the E2f1-4 genes
and gene products.
A role for E2F2 and E2F4 in Myc-induced
lymphomagenesis
Male Em-myc transgenic mice (backcrossed and maintained in
the C57BL/6 strain) were bred into the four different E2F-
deficient mouse lines. E2F2, E2F3 and E2F4 cohorts were
maintained as C57BL/66129 while the E2F1 cohort was
predominantly C57BL/6 in background. In particular, the E2F3
and E2F4 cohorts required maintenance on a mixed, rather than
inbred, background because the yield of the E2f3-null and E2f4-
null mice was severely compromised upon inbreeding (data not
shown). Sibling mice, wild type, heterozygous or null for a
particular E2F gene, and bearing the Em-myc transgene, were
examined weekly for any sign of lymphoma emergence. Each
mouse was checked for enlarged lymph nodes, a swollen abdomen,
a hunched posture, ruffled fur and/or tachypnea [22]. Upon the
appearance of any of these symptoms, the mouse was sacrificed,
dissected to identify any lymph node enlargement, and tumor
tissue harvested for analysis. For studies assessing the pre-tumor
phenotype, mice were sacrificed within three to five weeks after
birth and bone marrow and spleen recovered. Such samples were
characterized as pre-neoplastic only if lymph node and spleen
enlargement was nil or modest at the time of dissection and/or
Southern analysis of B lineage cell DNA revealed no specific heavy
chain rearrangements indicative of the emergence of tumor clones.
Tumor emergence was evaluated in the four E2F cohorts
(Figure 1), as well as for our Em-myc C57BL/6 congenic stock mice
(Figure S2A). When the wild type mice in each cohort were
compared to the stock transgenic mice, median onsets did diverge
(Figure S2B), with earlier onsets associated with greater 129 strain
contribution based on breeding history. In spite of this, the overall
Author Summary
The diversity of human cancers reflects the variety of
genetic changes that cause tumors to emerge and
progress. Even for mice engineered with a specific
cancer-causing mutation, the resulting tumors are often
divergent, reflecting different additional mutations. We
wanted to investigate how activities that work together
can collaborate in tumorigenesis. Specifically, we are
interested in Myc and the E2F family of proteins,
intersecting activities that influence a cell’s decision to
replicate, rest, or die. We made use of an engineered
mouse that develops pre-B and B cell lymphoma initiated
by Myc and tested whether the loss of particular E2F family
members influences these lymphomas. We found that
tumor emergence was accelerated by E2F2 loss and
delayed by E2F4 loss. We attributed these results to the
finding that the mice lacking E2F2 have a greater
proportion than usual of the most susceptible, early-stage
B lineage cells and the mice lacking E2F4 have fewer of
these cells. Distinct tumor types emerged with their
relative proportions influenced by E2F2 and E2F4 status.
We conclude that the variety of tumors probably reflect
different stages of B lymphoid development that respond
to Myc and that E2F proteins can influence the proportions
of these different stages.
E2F and Myc-Induced Lymphoma
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mice succumbing early and others succumbing late.
As shown in Figure 1A, the loss of E2F1 function did not alter
the timing of lymphoma appearance; there was no statistical
difference between tumor onset curves when comparing E2f1
+/+
(n=37), E2f1
+/2 (n=91) and E2f1
2/2 (n=40) mice. The failure
of E2F1 status to influence lymphomagenesis conflicts with the
earlier finding that E2F1 deficiency delays lymphoma develop-
ment in Em-myc mice [23]. That study attributed the delay to a
defect in p27
Kip1 degradation and reduced Myc-induced prolifer-
ation when E2F1 is reduced or absent. In our assessments the level
of p27
Kip1 protein in splenic B lineage cells did not vary according
E2F1 status but rather with progression to disease: p27
Kip1 was
highest in cells isolated from non-transgenic siblings, reduced in
healthy Em-myc transgenics, and lower still in very sick mice and
tumors (Figure S3A). In addition, the accelerated proliferation
induced by expression of the Em-myc transgene [24] was unaffected
by E2F1 deficiency: splenic B lineage cells isolated from E2f1 wild
type, heterozygous and null Em-myc transgenic mice all exhibited
the same dramatically higher proliferative index when compared
to that of cells isolated from non-transgenic siblings (Figure S3B).
We note that, analogous to our results, E2F1 deficiency did not
alter Myc-induced T cell lymphomagenesis [25]. Given that the
timing of Em-myc-driven tumor development can be influenced by
strain background [26] and breeding strategy, we can only surmise
that these potential differences or the specific E2f1-null allele
[27,28] used in our studies versus that of Baudino and colleagues
are sufficient to account for the discrepant effects of E2F1
deficiency.
As shown in Figure 1B, lymphoma onset was also not
appreciably influenced by E2F3 status. While the number of
E2f3-null animals was low in this study, reflecting the low number
of E2f3-null mice born, there is nevertheless no suggestion that
E2F3 loss was protective as several E2f3-null mice died before the
average age of onset for their wild type siblings.
In contrast to the results seen with the E2f1 and E2f3 knockout
animals, a deficiency of E2F2 dramatically accelerated the
appearance of lymphoma (Figure 1C). The E2f2
2/2 mice were
prone to early tumor onset with tumors appearing on average 60
days earlier than in their wild-type siblings and there was a
significant difference (p,0.0001) between the E2f2
+/+ and E2f2
2/2
tumor curves. Notably, the E2f2
+/2 mice exhibited a median
tumor-free span of 92 days and a significantly accelerated course
of disease compared to wild-type siblings (p,0.0001). The
Figure 1. Myc-induced lymphomagenesis is influenced by E2F
status. (A) Kaplan-Meier survival analysis showing the percentage of
tumor-free Em-myc mice with the indicated E2F1 genotypes (E2f1
+/+,
E2f1
+/2, and E2f1
2/2 sibling mice in the E2F1 cohort) plotted against
the onset of disease. Onset of disease did not vary with E2F1 status. (B)
Same as (A) but for E2f3
+/+, E2f3
+/2, and E2f3
2/2 sibling mice in the E2F3
cohort. Onset of disease did not vary with E2F3 status. (C) Same as (A)
but for E2f2
+/+, E2f2
+/2, and E2f2
2/2 sibling mice in the E2F2 cohort.
Disease onset was faster in E2f2
2/2 Em-myc mice (median age 63 days)
than in E2f2
+/+ Em-myc mice (median age 126 days), and the onset
curves were significantly different (P,0.0001). E2f2
+/2 Em-myc mice
exhibited an intermediate onset of disease (median age 92 days), and
the onset curve was significantly different from that of the E2f2
+/+ Em-
myc mice (P,0.0001) and the E2f2
2/2 Em-myc mice (P,0.0001). (D)
Same as (A) but for E2f4
+/+, E2f4
+/2, and E2f4
2/2 sibling mice in the E2F4
cohort. Disease onset was slower in E2f4
2/2 Em-myc mice (median age
375 days) than in E2f4
+/+ Em-myc mice (median age 110 days), and the
onset curves were significantly different (P,0.0001). Relative to the
E2f4
+/+ Em-myc mice, E2f4
+/2 Em-myc mice may have a slightly delayed
disease onset (P,0.0465).
doi:10.1371/journal.pgen.1000640.g001
E2F and Myc-Induced Lymphoma
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degree of haploinsufficiency. In addition, the E2f2
+/2 lymphomas
showed no loss of heterozygosity demonstrating that E2F2 does
n o tb e h a v el i k eac l a s s i ct u m o rs u p p r e s s o ri nt h eE m-myc context
(data not shown).
Finally, a deficiency in E2F4 also had a dramatic effect on Myc-
induced lymphoma development (Figure 1D). A comparison of
E2f4
+/+, E2f4
+/2 and E2f4
2/2 mice revealed that E2f4
2/2 mice
remained tumor-free for significantly longer than siblings
(p,0.0001) with a median tumor-free span of 375 days past
birth. Lymphoma onset may be modestly delayed in E2f4
+/2 mice
(p=0.0465).
Taken together, these data would suggest roles for two E2F
proteins, both positive and negative acting, in affecting the onset of
Myc-mediated lymphomas. A role for these two E2F family
members also coincides with the prominent expression of these
proteins in hematopoetic tissues (Figure S1).
Loss of E2F2 or E2F4 function does not alter Myc-
mediated proliferation or apoptosis
Previous work has shown that in the B cell lineage Myc induces
proliferation and apoptosis and retards differentiation [24,29]. As
such, the effects of E2F loss of function on Myc oncogenesis could
result from alterations in one or more of these processes. To
address the potential for differential effects on proliferation,
weanling mice were injected with BrdU, three hours later bone
marrow was isolated, and the cell cycle distribution of B lineage
cells (B220+ CD19+) determined. As shown in Figure 2A,
proliferation of B lineage cells was similar for non-transgenic
E2f2 wild type and null cells. Importantly, the effect of Myc on cell
cycle entry of B lineage cells, with increased S-phase cells and
reduced G0/G1 cells, was independent of E2F2 status. As shown
in Figure 2B, E2f4 wild type and null B lineage cells were similarly
proliferative in non-transgenic mice. As well there was still the
expected increase in proliferation associated with bearing the Em-
Figure 2. The cell cycle distribution of pretumorous B lineage cells is not altered by E2F2 or E2F4 status. (A) The cell cycle distribution
of bone marrow B lineage cells (B220+ CD19+) from pretumorous E2F2 cohort mice. The error bars indicate standard deviation. (B) The cell cycle
distribution of bone marrow B lineage cells (B220+ CD19+) from pretumorous E2F4 cohort mice. The error bars indicate standard deviation.
doi:10.1371/journal.pgen.1000640.g002
E2F and Myc-Induced Lymphoma
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2/2 compared to E2f4
2/2
Em-myc+: p=0.0002) (Figure 2B). It appears that the acceleration
of cell cycle progression driven by Myc in B lineage cells is not
significantly affected by the loss of E2F2 or E2F4 activities.
An alteration in the apoptotic potential of Myc could account
for the differences in Myc-initiated tumor onset among wild type,
E2f2-null and E2f4-null animals. Possibly in E2f2
2/2 mice
apoptosis is reduced whereas in E2f4
2/2 mice apoptosis is
potentiated. Freshly isolated bone marrow B lineage cells
(B220+) from E2f2
2/2 Em-myc transgenics and E2f4
2/2 Em-myc
transgenics were found to have comparable percentages of
activated caspase-3 positive cells as their wild type and
heterozygous Em-myc siblings, around 0.6%, and all the non-
transgenic siblings had less than half this percentage of apoptotic
cells (data not shown). Since divergent viability may be masked by
clearance in vivo, the survival of B lineage cells under culture
conditions where deregulated Myc induces apoptosis was assessed
[30,31]. The bulk of B lineage cells, excepting progenitors
upstream of small pre-B cells, was enriched by negative selection
from the bone marrow, spleen and mesenteric lymph node. The
resulting population of small pre-B cells, immature B cells and
mature B cells from each mouse was cultured for eight hours in
medium lacking cytokines. The cultured cells were sampled at two-
hour intervals, and B220+ cells assessed for viability based on
activated caspase 3 and 7-AAD staining (Figure S4). As expected,
the decline in viability was faster for cells from Em-myc transgenics
than from non-transgenics (Figure S4 and Figure 3A and 3B).
Notably, when mice in the E2F2 cohort were compared, cells from
E2f2
2/2 Em-myc mice lost viability to a similar extent over eight
hours as cells from wild type and heterozygous siblings (Figure 3A).
Likewise, in an experiment assessing E2F4 cohort mice, cells from
E2f4
2/2 Em-myc mice declined in viability similarly to those from
their wild type and heterozygous siblings (Figure 3B). Thus, the
faster tumor onset for E2f2-deficient mice appears not attributable
to a general apoptotic deficiency and the slower tumor onset for
E2f4-null mice unlikely the result of increased apoptosis, at least in
the small pre-B cells and more mature stages assessed here that
constitute the large majority of B lineage cells.
Myc-mediated tumor emergence is almost invariably associated
with a disabling of the ARF-p53 tumor suppressor pathway [8,14].
Mutations that are indicative of pathway disruption include: p53
deletion, ARF deletion, or overexpression of ARF, Mdm2 or
mutant p53. Examples of these disruptions in a sampling of tumors
are shown in Figures S5, S6, and S7. Consistent with the earlier
studies, tumors from E2F wild type Em-myc mice showed evidence
of disruption of the ARF-Mdm2-p53 pathway (Figure 3C). The
largely late-onset lymphomas from E2f4-null mice also demon-
strated disruptions in this pathway. Importantly, the spectrum and
overall incidence of defects in the E2f2
+/2 and E2f2
2/2
lymphomas were very similar to that shown by the E2f2
+/+
lymphomas. In contrast, other modifiers of Myc-induced lympho-
magenesis such as Bim and Bax relieve or modify the strong
selective pressure for functional inactivation of this pathway
[32,33]. That loss of ARF-p53 function was still associated with
development of tumors in the E2f2
2/2 mice further supports the
evidence that E2F2 deficiency does not compromise Myc-induced
apoptosis (Figure 3A).
Expansion of B lineage progenitor populations in E2f2
2/2
mice
Given that E2F2 deficiency does not alter the proliferation or
apoptosis of pretumorous B lineage cells in response to Myc, we
focused on the possibility that there may be a different underlying
mechanism driving the accelerated tumor emergence, one
involving development of the B lineage and the response to
Myc. As noted in one of the earliest descriptions of the Em-myc
model, it is possible that different onsets could reflect different
extents of lineage expansion in response to Myc and therefore
numbers of vulnerable cells [24]. Overall viable white blood cell
number in the bone marrow did not change with E2F2 status
while Em-myc positive mice had modestly higher counts (data not
shown). As expected, the B cell lineage expanded as a proportion
of the bone marrow in response to the Em-myc transgene in E2f2
+/+
mice (Figure 4A) and the expansion favored less mature over more
mature B cells across all three genotypes (Figure 4B). Importantly,
there was a similar degree of expansion for the E2f2
+/2 and
E2f2
2/2 mice.
Recent studies have suggested, however, that lymphomagenesis
likely initiates in B lineage progenitor cells making the effects of
various mutations on progenitor populations particularly relevant
[34]. For instance, the Em-myc bcl2
2/2 mice develop tumors at the
same rate as Em-myc bcl2
+/+ mice despite decreased pre-B,
immature B and mature B lymphocytes; significantly, they do
have similar numbers of pro-B cells [34]. Similarly, Em-myc/max41
mice develop lymphoma almost as quickly at Em-myc mice despite
a severe deficit in more mature, peripheral B cells [35].
Conversely, the increased progenitor population of early/large
pre-B stage cells exhibited by Phospholipase Cc2-deficient mice is
associated with accelerated lymphomagenesis [36]. As shown in
Figure 4C, CFU pre-B colony assays using bone marrow from
non-transgenic E2F2 cohort mice indicate that there were more B
lineage progenitors in E2f2
2/2 marrow (P,0.0001) and E2f2
+/2
marrow (P=0.0406) than wild type marrow. The proportion of
early B lineage cells (B220+ CD43+) identified by flow cytometry
was also greater in non-transgenic E2f2
2/2 marrow than in non-
transgenic E2f2
+/+ marrow (P=0.0008; Figure 4D). The increased
proportions of progenitors in E2f2-deficient mice extended into
pre-tumorous Em-myc positive mice: there was the trend, although
not statistically significant, for more immature B lineage cells as a
proportion of the total bone marrow in E2f2
2/2 (P=0.0769) and
E2f2
+/2 Em-myc transgenics (P=0.1393) compared to E2f2
+/+ Em-
myc transgenic mice (Figure 4D).
Additional analysis revealed that a significant proportion of the
E2f2
2/2 Em-myc lymphomas were not monoclonal. Assessment of
Igh locus rearrangement patterns by Southern analysis indicated
that almost 40% of the E2f2
2/2 tumors were biclonal or
oligoclonal whereas tumors from other genotypes, whether in
the E2F2 cohort or in other cohorts, were predominantly
monoclonal, in agreement with past studies [5] (Figure 5A and
Figure S8A and S8B). This degree of oligoclonality was, however,
less extensive than that which occurs with the homozygous Em-
myc/Em-myc mice [37] and when retrovirally-expressed myc was
expressed in mice reconstituted with p532/2 hematopoietic stem
cells [38]. In addition, several tumors were analyzed by flow
cytometry for isotypic surface marker expression (Figure 5B).
Seven out of ten tumors emerging from E2f2
2/2 mice displayed a
complex pattern of isotypic surface markers. Such complexity,
while not uncommon for Em-myc lymphomas in general [22], is
consistent with multiple clones. Of note, two out of eight tumors
from E2f2
+/2 mice were similarly complex. In contrast, the
majority of tumors from other Em-myc mice displayed single,
homogeneous patterns of surface markers and could be clearly
classified as being either pro/pre-B or immature B lymphomas.
Taken together, these findings support the conclusion that in the
E2f2
2/2 Em-myc mice there is an increased population of B lineage
cells susceptible to lymphomagenesis resulting in the occasional
emergence of more than one independent tumor. Using a different
Myc transgenic system, Cory and colleagues noted the emergence
E2F and Myc-Induced Lymphoma
PLoS Genetics | www.plosgenetics.org 5 September 2009 | Volume 5 | Issue 9 | e1000640Figure 3. E2F2 and E2F4 do not influence the viability of pretumorous B lineage cells or the incidence of p19Arf-Mdm2-p53
alterations in Myc-induced lymphomas. (A) Representative experiment assessing the viability of B lineage cells (small pre-B and more mature
stages) isolated from pretumorous mice of the E2F2 cohort and cultured in the absence of cytokines. Flow cytometry was used to assess viability over
time in culture, with B220+ cells negative for both activated caspase 3 and 7-AAD identified as viable. Error bars show standard deviations. (B)
Representative experiment assessing the viability of B lineage cells (small pre-B and more mature stages) isolated from pretumorous mice of the E2F4
cohort and cultured in the absence of cytokines. Error bars show standard deviations. (C) Incidence of p53, p19ARF, and Mdm2 alterations in the
lymphomas emerging from Em-Myc transgenic mice of the indicated E2F genotypes. p53 and p19ARF deletions were identified by Southern blotting,
and p53, p19ARF, and Mdm2 overexpression by western blotting. As p19ARF overexpression can result from loss of p53 function, tumors were
counted as having p19ARF overexpression only when independent of p53 mutation or deletion. Mdm2 overexpression was counted only if exclusive
of defects in p53 or p19ARF.
doi:10.1371/journal.pgen.1000640.g003
E2F and Myc-Induced Lymphoma
PLoS Genetics | www.plosgenetics.org 6 September 2009 | Volume 5 | Issue 9 | e1000640Figure 4. Overall expansion of the B-lineage in response to Myc is not altered by E2F2 status, but E2f2-deficient mice have more
progenitor B cells. (A) The percentage of B-lineage cells (B220+) within the bone marrow of normal and pretumorous mice with the indicated
genotypes. (B) Proportions of bone marrow B lineage cell populations (B220+), from early to more mature stages, across the E2F2 cohort: surface
immunoglobulin negative cells, IgM positive IgD negative cells, IgM positive IgD positive cells, and IgM negative IgD positive cells. (C) For clonogenic
pre-B cell progenitor assays, an equivalent number of whole bone marrow cells from 8-week old E2f2
+/+, E2f2
+/2, and E2f2
2/2 littermates were plated
in methylcellulose formulated for pre-B progenitors. After seven days, the number of progenitors (CFU pre-B) per 5610
4 input cells was determined
by counting the B lineage colonies that had arisen. (D) The proportion of immature B lineage cells (B220+ CD43+) in the bone marrow of normal and
pretumorous E2F2 cohort mice of the indicated genotypes.
doi:10.1371/journal.pgen.1000640.g004
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mixed tumors originated as separate clones and could be expected
with a high rate of tumorigenesis [39]. Also consistent with the
hypothesis that the enhancement of early onset tumors in E2f2
2/2
mice is the consequence a larger pool of susceptible cells, rather
than of differently behaving cells, is the finding that the
lymphomas that emerged were very similar to lymphomas that
arose early in E2f2
+/+ Em-myc mice. For instance, when mice
Figure 5. Analysis of E2F2 cohort lymphomas shows that some E2f2-null Em-myc transgenic tumors are polyclonal. (A) The clonality of
lymphomas as indicated by the pattern of immunoglobulin heavy chain rearrangements in Southern blotting. Lymphomas were characterized as
monoclonal if there were zero, one, or two bands in addition to the residual genomic band, as biclonal if there were three or four bands in addition to
the genomic band, and as oligoclonal if there were five or more bands in addition to the genomic band. (B) Flow cytometric analysis of lymphomas.
Top panels, an E2f2
+/+ Em-myc transgenic lymphoma and bottom panels, an E2f2
2/2 Em-myc transgenic lymphoma. The tumor cells were stained to
identify mature B cell subsets defined by B220 and CD19 and surface expression of IgM and IgD.
doi:10.1371/journal.pgen.1000640.g005
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was comparable (Figure S9A) and the histopathology of the
lymphomas was similar. The majority of early-onset tumors, either
from E2f2
+/+ or E2f2
2/2 mice, featured high mitotic indices and
extensive apoptosis with tingible body macrophages and a starry
sky appearance similar to that of human Burkitt lymphoma (data
not shown). In addition, B lineage cells (B220+) isolated from
E2f2
+/+ and E2f2
2/2 lymphomas exhibited comparable rates of
proliferation and apoptosis (Figure S9B and S9C).
Reduced populations of B lineage progenitors in E2f4
2/2
mice
It has recently been shown that E2f4-deficient mice have defects
that extend from early hematopoietic progenitor cells, through
common lymphoid precursors and into the B and T lineages [40].
Specifically in the B lineage, E2f4
2/2 mice exhibit a partial block
early in B lineage development prior to immunoglobulin gene
rearrangement that results in a deficiency in the most mature pro-
B subpopulation and a reduction in more mature B lineage cells
[19] (Glozak et al., manuscript in preparation).
Total viable white blood cell counts in the bone marrow were
modestly higher for Em-myc E2f4
+/+ and E2f4
+/2 mice than for non-
transgenic siblings. In the case of E2f4
2/2 mice, there was no
increase associated with the Em-myc transgene and Em-myc E2f4
2/2
mice had about half as many cells as Em-myc wild type siblings
(p=0.0269). As expected, within the bone marrow, non-transgenic
E2f4
2/2 mice had alowerproportionofB lineagecellscomparedto
non-transgenic E2f4
+/+ mice (P=0.0133, Figure 6A). Strikingly, the
usual expansion of the B lineage in response to the myc transgene
failed to occur in the E2f4
2/2 mice. As a consequence, the
proportion of B lineage cells in the bone marrow was significantly
less in E2f4
2/2 Em-myc mice than in E2f4
+/+ Em-myc mice
(P=0.0019). Myc did, however, elicit the usual reduction in the
relative proportion of mature to less mature B lineage cells in the
E2f4-deficient miceas inE2f4 wild type mice(Figure 6B). Motivated
by the hypothesis that Em-myc lymphomas originate in early stage B
lineage cells [34], we assessed progenitor populations in the E2f4
2/2
mice compared to their siblings. In CFU pre-B colony assays using
bone marrow from non-transgenic E2F4 cohort mice, there were
significantly fewer progenitors in E2f4
2/2 marrow than wild type
marrow (data not shown; Glozak et al., manuscript in preparation).
Notably, the pre-tumorous E2f4
2/2 Em-myc mice exhibited no
expansion of immature B lineage cells (B220+ CD43+)a sa
proportion of the total bone marrow compared to their non-
transgenic E2f4
2/2 siblings (Figure 6C). We suggest that the Myc
transgenefailstoovercometheinefficientdevelopmentalprogression
of the B lineage in E2f4-deficient mice, there is a reduced number of
susceptible progenitor cells, and consequently delayed tumor
emergence.
As indicated by Figure 1D, E2f4
2/2 Em-myc mice displayed a
much delayed tumor onset. Possibly because of this delay, of the
twenty-six mice assessed, nine died before lymphoma emergence
or were still healthy at analysis. The three mice that developed
lymphoma early (within 150 days of birth) and one older mouse
exhibited the standard Em-myc lymphoma phenotype, character-
ized by an enlarged spleen and multiple enlarged lymph nodes.
Thirteen mice developed lymphoma very late in life. Three of
these mice exhibited lymphoma with modest spleen enlargement
and isolated lymph node enlargement, similar the uncommon late
onset lymphomas that occasionally develop in Em-myc mice wild
type for E2F. The ten remaining E2f4
2/2 Em-myc mice displayed
an atypical tumor phenotype that was only rarely noted in E2F
wild type Em-myc mice (10 of 17 E2f4
2/2 mice compared to only 3
of 79 E2f4
+/+ mice). These atypical tumors featured a loose tumor
Figure 6. E2f4 deficiency limits expansion of the B lineage in
response to Myc. (A) The percentage of B lineage cells (B220+) within
the bone marrow of normal and pretumorous E2F4 cohort mice with
the indicated genotypes. (B) Proportions of bone marrow B lineage cell
populations (B220+), from early to more mature stages, across the E2F4
cohort: surface immunoglobulin negative cells, IgM positive IgD
negative B cells, IgM positive IgD positive B cells, and IgM negative
IgD positive B cells. (C) The proportion of immature B lineage cells
(B220+ CD43+) in the bone marrow of non-transgenic and pretumorous
E2F4 mice of the indicated genotypes.
doi:10.1371/journal.pgen.1000640.g006
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associated spleen or peripheral lymph node enlargement. Despite
their unusual appearance, the atypical tumors that were tested
demonstrated Igh gene rearrangement confirming their B
lymphoid origin. Overall, eleven E2f4
2/2 tumors, including
examples of standard, late, and atypical types, were assessed for
clonality and all proved to be monoclonal. In summary, along with
the general delay in tumor onset there was also a difference in the
predominant site of lymphomagenesis and gross morphological
appearance of tumors in the E2f4
2/2 Em-myc mice.
Distinct types of B lineage lymphoma that are influenced
by the presence of E2F2 or E2F4
As a further basis for exploring the effects of E2F loss of function
on the development of Myc-induced tumors, we have made use of
genome-scale gene expression profiles to characterize the tumors
arising in the E2f2-null and E2f4-null Em-myc mice. Our recent
work has identified expression profiles that distinguish different
tumor types within the Em-myc mice including a cluster
characterized by generally early onset and pre-B markers as well
as three distinct clusters characterized by late onset and different
sets of more differentiated B lineage markers [41]. Examples of
wild type tumors exhibiting this early and late onset pattern are
shown in Figure 7A. Analysis of the tumors from the E2f2
2/2
mice indicated that they were relatively homogeneous with respect
to their expression profiles and reflected the characteristics of the
‘‘early’’ category of wild type tumors. In contrast, the tumor types
from the E2f4
2/2 mice were heterogeneous with a distribution
across both broad categories of the wild type tumors. The
distribution of the E2f4
2/2 tumors corresponded with their
dissection phenotypes - standard, late and atypical - described
above. Three early-onset E2f4
2/2 tumors, all with the standard
morphological phenotype, clustered with the ‘‘early’’ wild type and
E2f2
2/2 tumors. Three more E2f4
2/2 tumors, all with the late
morphological phenotype, clustered alongside a group of wild type
tumors that overexpress genes characteristic of plasmacytomas.
These particular E2f4
2/2 tumors shared marginally decreased myc
mRNA and low Myc protein compared to other E2f4
2/2 tumors
(data not shown). The final six E2f4
2/2 tumors were all of the
atypical phenotype and segregated in the ‘‘early’’ category despite
being late onset chronologically. These tumors shared qualities
with the ‘‘early-standard’’ tumors in that they featured high levels
of myc mRNA and Myc protein (data not shown). Notably, these
tumors fell at the extreme end of the early cluster and beside a rare
group of wild type tumors that had similarly modest spleen
enlargement and late chronological onset. In fact, these tumors
highlight a significant subgroup within the ‘‘early’’ category that
we have designated ‘‘early-atypical’’. This tumor subgroup was
notable for a high incidence of p53 deletion or mutation (67% of
tumors assessed versus 18% of other wild type tumors assessed; by
Fisher’s exact test P=0.0061). Among the genes that characterized
each tumor cluster, increased expression of number of genes
distinguished this subgroup from both ‘‘early-standard’’ and ‘‘late’’
clusters (Figure S10). Cdkn2a, the locus that encodes the two tumor
suppressors p16(INK4a) and p19(ARF), was preferentially ex-
pressed in these tumors. Given that most of these tumors were
mutant for p53, the increased expression may be a consequence of
a role for p53 in negatively regulating the expression of ARF [42].
Other genes that were particularly highly expressed in the ‘‘early-
atypical’’ tumors included Dlk1, a member of the epidermal
growth factor-like family that influences B lineage differentiation
[43,44] and Fzd6, a receptor for Wnt signaling and a frizzled
family member [45].
To further characterize the distinctions in the Em-myc tumors,
we have made use of signatures of various cell signaling pathways
that have previously been shown to distinguish human Burkitt
lymphoma (BL) from diffuse large cell B lymphoma (DLBCL) [46].
These include signatures for Myc pathway activity, the expression
of a subgroup of germinal-center B-cell genes, the expression of
MHC class I genes, and NFkB pathway activity. An analysis of
tumors from the E2f2-null and E2f4-null mice using these pathway
signatures is shown in Figure 7B. Consistent with the analysis of
whole genome gene expression data in Figure 7A that revealed
distinct types of B lymphoma, the analysis using pathway
signatures also revealed that the tumors from the E2f2-null mice
exhibited a pattern similar to the ‘‘early’’ tumors, characterized by
high Myc and germinal center signatures, whereas the tumors
from E2f4-null mice were heterogeneous with respect to these
patterns. The atypical E2f4
2/2 tumors did not feature the usual
‘‘late’’ characteristics but instead had elevated Myc and germinal
center signatures and low MHC Class I and NF-KB signatures.
These tumors highlight the existence of certain tumors of late
chronological onset, whether E2F wild type or E2f4
2/2, that were
unusual in their behavior.
Discussion
A dominant characteristic of the oncogenic process is
complexity – the realization that the development of a tumor
results from a complex array of genetic alterations that ultimately
combine to contribute to the oncogenic phenotype. While
transgenic mouse models reduce this complexity by fixing one
event, various studies have shown a clear heterogeneity in the
tumors that develop reflecting the acquisition of additional
alterations. Based on the studies we describe here, we suggest
that there are at least two distinct types of B lineage lymphoma
that develop in the Em-myc mice. In mice with wild type E2F
function, the predominant tumor arising with an early onset likely
reflects the relative abundance of the target cell population. We
suggest that the emergence of these tumors reflects a stochastic
acquisition of additional mutations. Since this is a probabilistic
event, there is then an opportunity for tumors to emerge from
other populations of cells with characteristics distinct from the
‘‘early-standard’’ tumors. We propose that the late-onset tumors
develop more slowly because the target cell populations are less
abundant. It is also possible that these late-onset tumors are
genetically more complex, requiring more mutations than the
predominant form of tumors.
The work we present here provides clear evidence for an
interaction between Myc and two E2Fs as seen by the effect on
timing of tumor onset and the different characteristics of the
lymphomas that arise in the absence of E2F2 or E2F4. The results
suggest distinct roles for the E2F2 and E2F4 proteins in the process
of B lineage development that then impacts Myc-mediated
oncogenesis. A role for E2F4 in cell differentiation is consistent
with past work that documented abnormalities in hematopoietic
lineage development as well as the development of the gut and
nasal epithelia with loss of E2F4 activity [19,40,47–49]. This past
work revealed a deficiency of various mature hematopoietic cell
types and defects in the differentiation of immature cells in the
absence of E2F4. Taken together, these observations suggest a
critical role for E2F4 activity in controlling the maturation of
hematopoietic lineage cells, including the B lymphoid compart-
ment that generates the target cells for Em-myc-induced lympho-
magenesis.
A role for E2F2 appears to be more complex. E2F2 has
generally been characterized as one of the E2Fs involved in the
E2F and Myc-Induced Lymphoma
PLoS Genetics | www.plosgenetics.org 10 September 2009 | Volume 5 | Issue 9 | e1000640Figure 7. Distinct forms of Em-myc lymphomas. (A) Unsupervised hierarchical clustering of E2f2
2/2 and E2f4
2/2 Em-myc lymphomas amongst
E2F wild type Em-myc lymphomas. Dendrogram of tumor subsets and heat map of the expression pattern of 958 genes used for the clustering
analysis. Genes with sufficient variation in their expression across wild type (n=50 plus 8 duplicates), E2f2
2/2 (n=11), and E2f4
2/2 (n=12) tumors
were used to identify subgroups of tumors by two-way clustering. The tree classifies the tumors according to similarity of gene expression and
identifies two major tumor clusters. The associated time of onset is shown by a color map (red=early onset and blue=late onset). The E2f2
2/2 and
E2f4
2/2 Em-myc lymphomas and their dissected tumor phenotypes (Standard, Atypical, and Late) are identified. (B) Pathway expression signatures
that characterize the distinct forms of Em-myc lymphomas. E2F wild type lymphomas (n=50), E2f2
2/2 lymphomas (n=11), and E2f4
2/2 lymphomas
(n=12) were classified on the basis of Myc pathway activity, the expression of a group of germinal-center B-cell genes, the expression of major-
histocompatibility-complex class I genes, and NF-KB pathway activity. The associated dissected tumor phenotypes (Standard, Atypical, or Late) for the
E2f4
2/2 Em-myc lymphomas are indicated.
doi:10.1371/journal.pgen.1000640.g007
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While the other two activating E2Fs (E2F1 and E2F3) appear to be
broadly expressed, E2F2 expression is largely restricted to cells of
the hematopoietic lineage. Indeed, previous work has pointed to a
role for E2F2 in the function and development of various
hematopoietic lineages. S-phase progression is impaired in B,
erythroid, and myeloid lineages in the absence of E2F1 and E2F2,
consistent with a role for these E2F products as positive regulators
of cell proliferation [50]. Nevertheless, the possibility of a more
complex role for E2F2 in hematopoietic cells emerged from studies
demonstrating that the loss of E2F2 appears to enhance the
proliferation of T cells following antigenic stimulation, suggesting a
negative role for E2F2 in defining a threshold for Ag-stimulated
proliferation [51,52]. Although this latter observation is not
consistent with the results we present here regarding proliferative
capacity in E2f2-null B lineage cells, it certainly is true that with
Myc overexpression, the absence of E2F2 function may accelerate
tumor onset by increasing the proportion of progenitor B lineage
populations.
Opavsky and colleagues have recently used a bitransgenic
model of Myc-induced T cell lymphomagenesis to probe the
importance of E2F1, E2F2 and E2F3 for Myc activities [25].
Analogous to our findings for B lineage lymphomagenesis, they
found that E2f1 or E2f3 deficiencies have no effect on T cell
lymphoma progression. Most importantly, E2f2 deficiency accel-
erates tumor onset in the T cell model as it does for the Em-myc
model. In addition, other aspects of their findings are reminiscent
of our results, namely that E2f2 heterozygotes have an
intermediate phenotype, suggesting some haploinsufficiency, and
that with E2f2 deficiency there is an increased incidence of
multiple tumor clones. The salient difference is that in their study,
E2f2 deficiency is associated with reduced apoptosis. Specifically,
Opavsky and colleagues detected a reduced percentage of
annexin-positive T cells in moribund mice that were E2f2
2/2
versus E2f2
+/+ whereas in our experiments, E2f2 deficiency was
not associated with reduced apoptosis, whether assessing the bulk
of B lineage cells from pretumorous mice, or when looking at
B220+ cells isolated from tumorous lymph nodes (Figure 3A and
Figure S9C).
In marked contrast to the study of Baudino et al. [23], the work
described here did not demonstrate that E2f1 deficiency influenced
lymphoma development or p27
Kip1 regulation. This discrepancy
could be the consequence of the different knockout alleles utilized
and possible differences in strain background and breeding
strategies. But we also note that the wild type E2f1 Em-myc mice
in the Baudino et al. study [23] exhibit a more precipitous and
overall earlier tumor-onset curve than reported in most other
studies with C57BL/6 congenic, wild type Em-myc mice.
Developmental effects that influence the outcome of
oncogenesis
Our results indicate that E2f2 deficiency enhances the
emergence of the ‘‘early-standard’’ form of lymphoma likely
because the absence of E2F2 activity expands the population of
cells that is the usual target for the oncogenic process in the Em-myc
model. As a result, the population of E2f2
2/2 tumors is also more
homogeneous with respect to their phenotype, as reflected by the
gene expression profiles. In contrast, we propose that the loss of
E2f4 results in the decrease of this population of cells and thus the
frequency of appearance of standard morphology early onset
tumors. There is not a complete absence of these cells since a few
tumors do arise in the absence of E2F4 that cluster with the ‘‘early-
standard’’ wild type and E2f2
2/2 tumors. But the consequence of
this depletion is enrichment for tumors with a late chronological
onset, whether to the extreme of the ‘‘early’’ cluster or in the
‘‘late’’ cluster, likely due to an opportunity for these tumors to
develop because of the reduced frequency of the ‘‘early-standard’’
variety. Taken together, these results point to a role for E2F
activities in determining the population of B lineage cells that
contribute to the development of tumors and highlights the
interplay between two cell regulatory activities, E2F and Myc, in
determining the outcome of the oncogenic process.
Materials and Methods
Mouse strains and tumor monitoring
Mice were housed in a Duke University Medical Center
Division of Laboratory Animal Resources facility and experiments
approved by the Duke University Institutional Animal Care and
Use Committee. The generation of the specific lines of E2F-
deficient mice has been previously described [19,28,53]. The
original 129 substrain background was 129/SvJae for the E2F1,
E2F2 and E2F3 cohorts and 129/OlaHsd for the E2F4 cohort.
Based on breeding history, the E2F1 cohort mice used in this study
were predominantly C57BL/6 (backcrossed five generations into
C57BL/6) while the E2F2, E2F3 and E2F4 cohorts were mixed
C57BL/66129. The four E2F cohorts were maintained separately
and breeding involved crossing heterozygous mice to yield wild
type, heterozygous and null mice in each generation.
The Em-myc transgenic mouse line 292-1 [5] extensively
backcrossed into C57BL/6 and originally from Dr. Alan Harris
(Walter and Eliza Hall Institute, Melbourne, Australia), was kindly
provided by Dr. Scott Lowe (Cold Spring Harbor Laboratory). For
each E2F cohort, stock Em-myc positive C57BL/6 congenic males
were bred to E2Fn
+/2 females and of the progeny only the Em-myc
positive E2fn
+/2 males, designated the F1 males, were kept. These
F1 males, E2fn
+/2 myc
+, were then bred to E2fn
+/2 myc
2 females.
The Em-myc positive progeny of this cross, E2fn
+/+, E2fn
+/2, and
E2fn
2/2 were then compared. Because maternal transmission is
associated with reduced latency [34], transmission of the Em-myc
transgene was exclusively paternal in this breeding scheme. Em-myc
negative siblings were also kept as a source of related mice that
lacked myc transgene effects.
Em-myc positive mice were monitored weekly to identify any
mice with malignant disease. Mice were evaluated for any visible
or palpable lumps, a hunched posture, tachypnea, a swollen belly,
or ruffled fur and sacrificed promptly upon the appearance of any
such symptoms. Lymphomas that emerged were dissected from
sacrificed mice, washed in PBS, and frozen in liquid nitrogen or
processed for flow cytometric analysis. The frozen tissue provided
material for Southern and western analysis.
Statistical analysis
Tumor onset data refer to the time in days between birth and
the first indication of illness. Using GraphPad’s Prism program,
the time values were plotted to generate Kaplan-Meier survival
curves and the curves compared by a logrank test. For
comparisons of means and standard deviations, the paired student
t-test was performed and statistical significance was determined if
the p,0.05.
Western analysis
To assess alterations in p19ARF, Mdm2 and p53 protein
expression, lymphoma samples were dissected from morbid mice
and immediately frozen. Samples were then weighed, ground to a
powder in liquid nitrogen and resuspended in 60 mM Tris
(pH 6.8)/1% SDS at 1 ml per 0.2 g tumor weight, boiled,
sonicated, and any remaining debris removed by centrifugation.
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fibroblasts infected with the indicated adenoviruses for controls.
Protein was quantitated using the BCA Protein Assay Reagent Kit
(Pierce). Samples (150 mg) were boiled in sample buffer and
subjected to SDS-PAGE on 8.5% polyacrylamide gels for p53 and
Mdm2 assessment and 15% gels for ARF assessment. Western
analysis was performed as previously described [54]. The blots
were probed with antibodies specific for p53 (monoclonal antibody
Ab-1 OP03 at 1:1000, Calbiochem), p19ARF (polyclonal antibody
Ab-1 PC435 at 1:10,000, Calbiochem), and Mdm2 (polyclonal
antibody C-18 sc812 at 1:1000, Santa Cruz Biotechnology). Equal
protein loading was verified by staining blots with Ponceau Red
(0.2% ponceau red in 3% trichloroacetic acid).
Southern analysis
Genomic DNA was isolated from lymphomas, normal spleen
cells, tail samples and MEFs of specified genotypes. DNA (10 mg)
was digested with BamH1 (for the p53 locus), AflII (for the p19ARF
locus) or EcoRI (for the heavy chain locus). The restricted DNA
was separated by agarose gel electrophoresis (0.8% gels),
transferred to Hybond N+ membrane, and probed. The p53
probe was a human cDNA fragment (686 base pair DrdI-StuI
fragment extending from exon 4 to exon 10). The ARF probe was
the exon 1B portion of the ARF cDNA (kindly provided by Charles
Sherr). The heavy chain locus probe was the heavy chain J3-J4
joining region genomic fragment [37]. On occasion, to verify that
weanling mice were essentially tumor-free, genomic DNA isolated
from B lineage cells was assessed by Southern analysis for any
emergence of clonal heavy chain rearrangements.
FACS analysis
Mononuclear cells were harvested from the bone marrow of 3-
week-old littermates and from lymphomas that arose. Cells were
stained with various combinations of antibodies to IgD (11-
26c.2a), IgM (R6-60.2), CD19 (1D3), B220 (RA3-6B2), CD43 (S7),
BrdU, and active caspase-3. All antibodies and staining reagents
were from BD Biosciences. Cell staining procedures were
performed either manually or using a Biomek 2000 robotic fluid
handler (Beckman Instruments, Schaumburg, IL using a series of
mini-programs developed with BioWorks software (Beckman
Instruments). FACS analysis was performed on a FACSCalibur
device equipped with a 488 nm argon laser and a ,635 nm red
dye laser (Becton Dickinson (BD), San Jose, CA). Data was
analyzed using FlowJo Software (TreeStar, Palo Alto, Ca).
Cell cycle analysis of B lineage cells from normal and
pretumorous mice
Three hours before analysis, mice were injected with 100 mg/
kg BrdU. Bone marrow mononuclear cells were collected and
stained with the B220 and CD19 antibodies to identify B lineage
cells, with 7-AAD, and with anti-BrdU antibodies. BrdU Flow Kit
reagents and directions were followed (BD/Pharmingen). The
proportion of cells that had proceeded through S-phase, or resided
in G0/G1 or in G2/M phases was determined.
Viability assessment in culture of B lineage cells from
normal and pretumorous mice
Hematopoietic cells were harvested from the bone marrow,
spleen and mesenteric lymph node, combined and enriched for B
lineage cells using negative selection (SpinSep Mouse B Cell
EnrichmentCocktail,StemCell Technologies).Theantibodiesused
to label unwanted cell types for depletion were directed against
CD4, CD8, CD11b, CD49b, Gr-1, TER119 and CD43. The
approach yielded a subset of B lineage cells from the small pre-B
stage through more mature stages. These cells were cultured at
37uC for eight hours in DMEM plus 10%FCS/100 mML -
aspargine/50 mM 2-mercaptoethanol at a concentration of 4610
6
cells/ml. At selected time points cells were removed and stained
with 7-AAD and B220 antibody, fixed and permeabilized, stained
with activated caspase-3 antibody and analyzed by flow cytometry.
Viable cells were negative for both 7-AAD and activated caspase-3.
CFU Pre-B assays
Equivalent numbers of bone marrow cells from non-transgenic
4–6 week old mice were resuspended in Methocult M3630
(Stemcell Technologies) according to manufacturer’s specifications
to assay for pre-B cell colonies. This media, formulated for the
detection and counting of mouse pre-B progenitors in bone
marrow, is comprised of methylcellulose in Iscove’s MDM
supplemented with recombinant IL-7, 2-Mercaptoethanol, L-
glutamine, and fetal bovine serum. All samples were assayed in
duplicate. After seven days colonies were counted using an
inverted microscope. The count was based on the manufacturer’s
description of expected colony appearance - namely that colonies
are composed of at least 30 cells and that individual cells are tiny
and irregular to oval in shape.
DNA microarray analysis
RNA was extracted from lymphoma samples using Qiagen
RNeasy Kits (Qiagen). RNA sample integrity was verified by
agarose gel electrophoresis or using an Agilent 2100 Bioanalyser.
We prepared the targets for DNA microarray analysis and
hybridized to Affymetrix Mouse 430 2.0 GeneChip arrays
according to the manufacturer’s instructions and as previously
published. To allow merging of expression array results from
samples arrayed independently, some duplicate samples were
arrayed to provide reference samples and the expression values
standardized using ComBat [55]. The method for cross-platform
comparison across different versions of Affymetrix GeneChip
arrays was described previously [56].
Statistical analyses of microarray data
Hierarchical clustering and visualization were performed using
Gene Cluster 3.0 (http://bonsai.ims.u-tokyo.ac.jp/,mdehoon/
software/cluster/) and Java TreeView (http://jtreeview.sourceforge.
net/). Genes and tumors were clustered by average linkage using
uncentered correlation as the similarity metric. Analysis of expression
data was described previously [56]. In summary, we collected training
sets consisting of gene expression values of samples where the pathway
activity was known. We created gene expression signatures by choosing
the genes whose expression profiles across the training samples most
highly correlated with the phenotype. Then, to predict the status of the
phenotype on a tumor expression dataset, we fit a Bayesian probit
regression model that assigned the probability that a tumor sample
exhibited evidence of the phenotype, based on the concordance of its
gene expression values with the signature.
The Supporting Materials and Methods are available in Text S1.
Supporting Information
Figure S1 Tissue-specific expression of E2F family members. (A)
Comparison of the relative expression of i) E2f1 mRNA, ii) E2f2
mRNA, iii) E2f3a and E2f3b mRNAs, and iv) E2f4 mRNA across
several tissue types with the expression in bone marrow set to one.
Tissues: BM-bone marrow, S-spleen, T-thymus, M-mammary
gland, O-ovary, U-uterus, Lu-lung, and Br-brain. (B) Western blot
analysis of E2F2 protein in tissues from wild type and matched
E2F and Myc-Induced Lymphoma
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from wild type and matched E2f4-null mice.
Found at: doi:10.1371/journal.pgen.1000640.s001 (0.96 MB TIF)
Figure S2 Kaplan-Meier survival analysis of Em-myc C57BL/6
congenic mice compared to the Em-myc E2Fn wild type mice. (A)
Kaplan-Meier survival analysis showing the percentage of tumor-
free Em-myc C57BL/6 congenic mice plotted against the onset of
disease. (B) Kaplan-Meier survival analysis comparing the Em-myc
C57BL/6 congenics with the Em-myc E2F wild type mice from the
various cohorts.
Found at: doi:10.1371/journal.pgen.1000640.s002 (0.22 MB TIF)
Figure S3 Myc-induced degradation of p27
Kip1 and promotion
of proliferation appear independent of E2F1 status. (A) Western
blot analysis of p27
Kip1 in B lineage cells isolated from the spleens
of non-transgenic sibling mice and transgenic mice progressing to
illness, and from lymphomas. Note that actin levels decrease with
disease progression while tubulin levels increase with disease
progression. (B) Splenic B lineage cell proliferation in E2F1 wild
type, heterozygous and null mice with and without the Em-myc
transgene. Mice were injected with BrdU, spleens harvested
fourteen hours later, and the incorporation of BrdU into DNA in
splenic B lineage cells (B220+) assessed by flow cytometry.
Found at: doi:10.1371/journal.pgen.1000640.s003 (0.78 MB TIF)
Figure S4 Flow cytometric analysis of cultured B lineage cells
to assess viability on the basis of staining for activated caspase 3
and 7AAD. ` B lineage cells (small pre-B and more mature cells)
were isolated from the bone marrow, spleen, and mesenteric
lymph node and then cultured without cytokines. At indicated
times cells were sampled from the cultures and stained for flow
cytometry. The boxed region identifies viable B220+ cells. Note
that at time zero there were more caspase-positive cells isolated
from Em-myc positive animals than from non-transgenics and that
over time caspase-positive cells shifted to becoming 7-AAD
positive as well.
Found at: doi:10.1371/journal.pgen.1000640.s004 (0.74 MB TIF)
Figure S5 Southern analysis of the p53 locus in normal tail
DNA, MEF DNA, and tumor DNA. (A) A 6 kb species and a
larger 10 kb pseudogene species were detected upon probing a
BamHI digest of mouse genomic DNA using a p53 human cDNA
probe (exons 4 to 10). (B) The mobility of the p53 locus fragment
was altered in DNA isolated from p532/2 MEFs. (C) The
screening of several Em-myc lymphoma samples and identification
of a single tumor, #14, as having deleted p53. Overall, deletion of
p53 was rare in the tumors we assessed, in keeping with the
findings of Eischen et al. [8]. The larger 10 kb pseudogene species
was unchanged in the p532/2 MEFs or any of the tumors and
provided a convenient loading control.
Found at: doi:10.1371/journal.pgen.1000640.s005 (1.57 MB TIF)
Figure S6 Southern analysis of the ARF locus in normal tail
DNA and tumor DNA. (A) A 7.8 kb fragment representing the
ARF locus was detected when tail DNA was digested with AflII and
probed with ARF exon 1B [8]. (B) Assessment of several tumors for
ARF locus deletion. Tumor #15 exhibited biallelic deletion of
ARF, while tumor #14, deleted for p53 (Figure S5), retained ARF.
(C) The screening of additional Em-myc tumor samples for ARF
deletion.
Found at: doi:10.1371/journal.pgen.1000640.s006 (1.40 MB TIF)
Figure S7 Immunoblot analysis of p53, ARF, and Mdm2
expression in MEFs and Em-myc tumors. (A) p53 protein was
assessed in MEFs infected with either control adenovirus or
adenovirus expressing E2F1, and in several tumor samples. Forced
overexpression of E2F1 induces accumulation of p53 [13], and the
same species was evident in one of the tumors. The p53 protein
overexpressed in some Em-myc tumors represents mutant forms
that accumulate to very high levels because they fail to induce
Mdm2 to trigger their own destruction [8]. (B) ARF protein was
assessed in MEFs infected with various recombinant adenoviruses,
one of which was Ad-Arf, and, in several tumors, some of which
overexpress ARF. (C) p53, ARF, and Mdm2 expression assessed in
the same set of Em-myc tumors. While no specific controls were
used for Mdm2 protein, assorted species of the expected size and
complexity were identified using the antibody referenced by
Eischen et al. [8]. In common with earlier studies, p53
overexpression was associated with ARF overexpression, ARF
overexpression also occurred independently in additional tumors,
and Mdm2 overexpression patterns were complex.
Found at: doi:10.1371/journal.pgen.1000640.s007 (1.97 MB TIF)
Figure S8 Tumor clonality as determined by Igh locus
rearrangement patterns. (A) Normal spleen DNA and tumor
DNAs were digested with EcoRI, agarose gel fractionated, and
Southern analysis performed using a heavy chain joining region
probe. The arrow indicates the 6.5 kb germline fragment in
normal spleen DNA, while in tumor samples additional bands
were evident, representing rearranged Igh alleles. Most commonly,
in addition to the residual germline band, there were two
equimolar fragments bearing the heavy chain joining region that
resulted from recombination at both Igh alleles (see tumor 2 and
tumor 4). The single rearranged fragment seen for tumor 1
probably reflects two co-migrating fragments. In the case of tumor
3, the dominance of the germline band suggests that the sample
largely comprised normal cells, and indeed the notes describing
the dissection suggested that lymphoma had barely initiated. As
described in the figure legend for Figure 5A, lymphomas were
characterized as monoclonal if there were zero, one, or two bands
in addition to any germline band, as biclonal if there were three or
four bands in addition to any germline band, and oligoclonal if
there were five or more bands in addition to any germline band.
(B) As an additional example of this analysis, the Igh rearrange-
ment patterns for several E2f2
+/+ and E2f2
2/2 Em-myc tumors are
displayed.
Found at: doi:10.1371/journal.pgen.1000640.s008 (1.25 MB TIF)
Figure S9 The E2f2
2/2 mice exhibit standard Em-myc lympho-
ma. (A) Comparison at time of dissection of spleen weights from
tumor-bearing E2f2
+/+ (n=18), E2f2
+/2 (n=23), and E2f2
2/2
(n=16) mice and non-transgenic mice (n=9). (B) Proliferation of
B lineage (B220+) lymphoma cells. Tumorous mice were injected
with BrdU and two hours later lymphomas dissected. BrdU
incorporation into the DNA of B220+ lymphoma cells was
assessed by flow cytometry. (C) Apoptosis of B lineage (B220+)
lymphoma cells. Freshly isolated lymphoma cells and normal
lymph node cells were isolated and stained with 7-AAD and
antibodies to B220 and activated caspase 3. B220+ cells were
designated as apoptotic if positive for activated caspase 3 and
either negative or positive for 7-AAD.
Found at: doi:10.1371/journal.pgen.1000640.s009 (0.21 MB TIF)
Figure S10 The expression pattern of genes associated with the
Expression levels are displayed with genes as rows and samples as
columns and shown by a heatmap in which high expression is
indicated by red and low expression by green.
Found at: doi:10.1371/journal.pgen.1000640.s010 (0.36 MB TIF)
Text S1 Supporting materials and methods.
Found at: doi:10.1371/journal.pgen.1000640.s011 (0.06 MB
DOC)
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